TPBG
GILD icon

Turning Point Benefit Group’s Gilead Sciences GILD Stock Holding History

Turning Point Benefit Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27
Closed -$3.31K – 373
2025
Q4 		$3.31K Buy
27
+19
+238% +$2.31K ﹤0.01% 359
2025
Q3 		$889 Buy
+8
New +$909 ﹤0.01% 406

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Turning Point Benefit Group's GILD Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 27 shares — an estimated $3.31K sold.

Turning Point Benefit Group first reported a position in GILD in Q3 2025 and held it in 2 quarters. The position peaked at $3.31K in Q4 2025. 2,320 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Turning Point Benefit Group reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 27 Gilead Sciences shares in Q1 2026, an estimated $3.31K.
  • Turning Point Benefit Group first reported a position in Gilead Sciences in Q3 2025 and held it in 2 quarters.
  • Turning Point Benefit Group's Gilead Sciences position peaked at $3.31K in Q4 2025.
  • 2,320 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.